Skip to main content

View full-text article in PMC

. 2010 Mar 26;2:83–96. doi: 10.2147/cmar.s7540

Table 1.

Risk group survivals in phase 3 bevacizumab trials

Risk group (MSKCC)^a	Progression-free survival^*		Overall survival^*
Risk group (MSKCC)^a	AVOREN^b	CALGB 90206^c	AVOREN	CALGB 90206^d
Favorable
Bevacizumab + IFN-α	12.9 mos	11.1 mos	NA	32.5 mos
IFN-α	7.6 mos	5.7 mos	NA	33.5 mos
Intermediate
Bevacizumab + IFN-α	10.2 mos	8.4 mos	NA	17.7 mos
IFN-α	4.5 mos	5.3 mos	NA	16.1 mos
Poor
Bevacizumab + IFN-α	2.2 mos	3.3 mos	NA	6.6 mos
IFN-α	2.1 mos	2.6 mos	NA	5.7 mos

^*

Median; NA – not available.

^a

Motzer et al⁴³;

^b

Escudier et al⁵;

^c

Rini et al⁶;

^d

Rini et al.⁴⁴